Drug Profile
SM 10888
Alternative Names: SM-10888Latest Information Update: 30 Aug 2007
Price :
$50
*
At a glance
- Originator Sumitomo Pharmaceuticals
- Class Neuroprotectants; Nootropics
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 22 Nov 1999 No-Development-Reported for Alzheimer's disease in Japan (PO)
- 10 Apr 1995 A preclinical study has been added to the pharmacokinetics section
- 09 Nov 1994 Phase-II clinical trials for Alzheimer's disease in Japan (PO)